세계의 불면증 시장 보고서(2025년)
Insomnia Global Market Report 2025
상품코드 : 1824396
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

불면증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.0%를 나타내 65억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 세계적인 건강위기의 영향, 수면위생에 대한 의식의 높아짐, 정신건강과 웰니스의 중시, 수면건강에 대한 정부의 대처, 사회적 결정요인의 영향 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 수면 모니터링을 위한 디지털 건강 솔루션, 불면증을 위한 인지 행동 치료, 수면 상담을 위한 원격 의료, 1차 케어에 수면 위생 통합, 신규 치료 대상 조사 등이 있습니다.

향후 5년간의 성장률 6.0%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 벨기에와 중국에서 수입되는 이중 오렉신 수용체 길항제 및 수면 폴리그래프 검사 장비의 비용을 증가시키고, 수면장애 관리를 악화시키고 신경과 클리닉의 비용을 증가시킬 수 있기 때문에 미국 정신 의료를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

비즈니스 관련 스트레스 증가는 향후 불면증 시장 성장을 이끌 것으로 예측됩니다. 일 관련 스트레스는 작업 요구와 압력이 근로자의 자원, 능력 및 지식에 맞지 않을 때 발생하는 유해한 감정적 및 신체적 반응을 의미합니다. 이런 유형의 일의 스트레스는 불면증을 포함한 다양한 건강 문제로 이어질 수 있습니다. 불면증의 중증도에 따라 환자는 약물 요법과 인지 행동 치료과 같은 접근법으로 치료됩니다. 예를 들어, 2022년 10월 미국에 본사를 둔 심리학자의 조직인 미국 심리학회는 직장 스트레스가 여전히 큰 우려사항이었고, 직원의 77%가 지난 한 달 동안 일과 관련된 스트레스를 경험했다고 답했다고 보고했습니다. 게다가 57%가 감정적 피로(31%)와 같은 부정적인 영향을 보고하고 있으며, 이들은 종종 번아웃 증후군과 관련이 있습니다. 따라서 일 관련 스트레스의 급증은 불면증 시장 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Insomnia is a sleep disorder characterized by difficulties in falling or staying asleep. Depending on the duration of symptoms, insomnia can be categorized as either short-term (acute) or long-term (chronic). Various treatments, including drugs, digital therapeutics, and devices, are employed to address insomnia conditions.

The main therapy types for insomnia encompass non-pharmacological therapy and pharmacological therapy. Non-pharmacological interventions (NPI) or non-pharmacological therapies involve non-chemical interventions performed on and benefiting the patient, such as light therapy and exercise. The various drug classes utilized in pharmacological therapy include anti-depressants, melatonin antagonists, benzodiazepines, non-benzodiazepines, orexin antagonists, and others. These drugs are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The insomnia market research report is one of a series of new reports from The Business Research Company that provides insomnia market statistics, including insomnia industry global market size, regional shares, competitors with an insomnia market share, detailed insomnia market segments, market trends, and opportunities, and any further data you may need to thrive in the insomnia industry. This insomnia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insomnia market size has grown steadily in recent years. It will grow from $5 billion in 2024 to $5.22 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increased stress levels, prevalence of mental health conditions, shift work and irregular work hours, increased awareness and diagnosis, high consumption of stimulants.

The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to global health crisis impact, increasing awareness of sleep hygiene, emphasis on mental health and wellness, government initiatives for sleep health, influence of social determinants. Major trends in the forecast period include digital health solutions for sleep monitoring, cognitive behavioral therapy for insomnia, telehealth for sleep consultations, integration of sleep health into primary care, research on novel therapeutic targets.

The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. mental health care by increasing costs for dual orexin receptor antagonists and polysomnography devices imported from Belgium and China, potentially worsening sleep disorder management and raising neurology clinic expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in work-related stress is expected to drive growth in the insomnia market in the future. Work-related stress refers to harmful emotional and physical responses that arise when the demands and pressures of work do not align with a worker's resources, capabilities, or knowledge. This type of job stress can lead to various health issues, including insomnia. Depending on the severity of the insomnia, patients may be treated with medications or cognitive-behavioral therapies, among other approaches. For example, in October 2022, the American Psychological Association, a U.S.-based organization of psychologists, reported that workplace stress remains a significant concern, with 77% of employees indicating they experienced work-related stress in the past month. Additionally, 57% reported negative effects, such as emotional exhaustion (31%), which are often associated with workplace burnout. Therefore, the surge in work-related stress is propelling the growth of the insomnia market.

The growth of the insomnia market is also expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting for three months or more and worsening over time, often lead to comorbid conditions such as insomnia. Individuals with chronic conditions such as cardiovascular disorders, diabetes, and chronic pain frequently experience sleep-related issues. The rising prevalence of chronic diseases creates a demand for effective insomnia treatments and management strategies, contributing to the growth of the market. According to the National Center for Biotechnology Information in January 2023, the global number of people with chronic diseases is projected to reach 142.66 million by 2050, up from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is a significant factor driving the growth of the insomnia market.

A key trend in the insomnia market is the adoption of product innovation. Major companies in the insomnia therapeutics market are developing innovative treatments to maintain their market positions. For example, WELT, a Korea-based medical device company, received approval for its digital insomnia treatment device, WELT-I, in April 2023. WELT-I is designed to correct behavioral, psychological, and cognitive factors contributing to insomnia. It delivers treatment based on cognitive behavioral therapy (CBT), a first-line treatment for insomnia. The device, classified as software as a medical device (SaMD), analyzes sleep patterns, intervenes in patient behavior, and delivers personalized relaxation therapy for eight weeks to improve sleep quality and reduce tension and anxiety.

Major companies in the insomnia market are introducing new products, such as zaleplon-based insomnia drugs, to gain a competitive edge. Zaleplon, a non-benzodiazepine sedative-hypnotic medication, is used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon is known for its rapid onset of action, short half-life, and minimal impact on daily activities. The launch of Zaledeep Cap. aims to provide a new and effective treatment option for individuals suffering from insomnia in response to the increasing cases in modern society.

In August 2022, ResMed, a US-based medical equipment company, acquired Mementor to strengthen its sleep portfolio in Germany. This acquisition included somnio, a digital solution for insomnia, Germany's first and only permanently approved digital health application (DiGA) in sleep medicine. Somnio focuses on improving sleep in insomnia patients, addressing the care gap, and providing alternatives to prevailing drug therapy. Mementor, a Germany-based developer of digital insomnia therapy solutions, contributes to ResMed's overall commitment to enhancing sleep-related healthcare.

Major companies operating in the insomnia market include Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.

North America was the largest region in the insomnia market in 2024. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the insomnia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insomnia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insomnia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for insomnia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The insomnia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Insomnia Market Characteristics

3. Insomnia Market Trends And Strategies

4. Insomnia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Insomnia Growth Analysis And Strategic Analysis Framework

6. Insomnia Market Segmentation

7. Insomnia Market Regional And Country Analysis

8. Asia-Pacific Insomnia Market

9. China Insomnia Market

10. India Insomnia Market

11. Japan Insomnia Market

12. Australia Insomnia Market

13. Indonesia Insomnia Market

14. South Korea Insomnia Market

15. Western Europe Insomnia Market

16. UK Insomnia Market

17. Germany Insomnia Market

18. France Insomnia Market

19. Italy Insomnia Market

20. Spain Insomnia Market

21. Eastern Europe Insomnia Market

22. Russia Insomnia Market

23. North America Insomnia Market

24. USA Insomnia Market

25. Canada Insomnia Market

26. South America Insomnia Market

27. Brazil Insomnia Market

28. Middle East Insomnia Market

29. Africa Insomnia Market

30. Insomnia Market Competitive Landscape And Company Profiles

31. Insomnia Market Other Major And Innovative Companies

32. Global Insomnia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Insomnia Market

34. Recent Developments In The Insomnia Market

35. Insomnia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기